StonvexLoading…
StonvexStonvexStonvexCore line items from DOC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $200.34M | $603.99M | $448.24M | $297.78M |
Operating Income | $195.65M | $284.29M | $159.18M | $93.94M |
Net Income | $193.63M | $71.35M | $-42.62M | $74.50M |
EPS (Diluted) | $0.28 | $0.10 | $-0.06 | $0.11 |
Total Assets | $21.62B | $20.34B | $19.58B | $19.81B |
Total Liabilities | $12.56B | $12.03B | $11.32B | $11.22B |
Cash & Equivalents | $1.17B | $467.46M | $91.04M | $89.44M |
Free Cash Flow OCF − CapEx | Not available | $357.01M | Not available | Not available |
Shares Outstanding | 695.26M | 695.04M | 694.95M | 694.92M |